JNJ vs LLY
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | JNJ | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $270.24 | $1,255.40 | |
| Market cap as of 2026-08-24 | $651.3B | $1.18T | |
| P/E as of 2026-08-24 | 29.93 | 43.17 | JNJ lower |
| PEG as of 2026-08-24 | 3.39 | 1.48 | LLY lower |
| Net margin as of 2026-08-24 | +21.5% | +33.5% | LLY higher |
| Gross margin as of 2026-08-24 | +68.0% | +83.4% | LLY higher |
| Operating margin as of 2026-08-24 | +25.7% | +42.2% | LLY higher |
| ROE as of 2026-08-24 | +25.7% | +92.6% | LLY higher |
| ROA as of 2026-08-24 | +10.6% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-24 | 0.58 | 1.62 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.1% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +31.7% | LLY higher |
| Dividend yield as of 2026-08-24 | +3.1% | +0.8% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.20 | 0.46 | |
| 1-year return as of 2026-08-21 close | +51.0% | +76.9% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.